Informations générales (source: ClinicalTrials.gov)
French Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis. (DUPILAB)
Observational
Sanofi (Voir sur ClinicalTrials)
novembre 2023
novembre 2027
03 octobre 2024
This is a long-term study to collect data over 3 years in order to find out what is
likely to happen in the future regarding participants 6 years of age and older who
receive dupilumab for Atopic Dermatitis (AD) commonly known as Eczema, and to
characterize real-world effectiveness, safety and use patterns of dupilumab in real world
setting in France. Patients will be invited to participate if initiating treatment with
dupilumab for AD according to French-specific prescribing information. The decision of
initiation of the treatment is independent to the study's participation. The study will
be conducted in approximately 50 centers in France to evaluate a representative sample of
patients treated in France. At each participating site, all AD participants who receive
an initial prescription for dupilumab will be invited to participate in this study, until
the enrollment goal is achieved.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL NOVO | BEGON | 04/07/2024 11:04:57 | Contacter | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Investigational Site Number: 2500001 - 25000 - Besançon - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500002 - 87042 - Limoges - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500003 - 69500 - Bron - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500004 - 74374 - Epagny Metz Tessy - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500005 - 21079 - Dijon - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500006 - 63003 - Clermont Ferrand - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500008 - 76038 - Rouen - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500009 - 24000 - Périgueux - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500010 - 26953 - Valence - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500011 - 57530 - Ars Laquenexy - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500012 - 31059 - Toulouse - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500013 - 97448 - Saint-Pierre - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500014 - 26102 - Romans sur Isère - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500015 - 78100 - Saint Germain en Laye - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500016 - 64000 - Pau - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500018 - 62022 - Arras - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500019 - 76290 - Montivilliers - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500020 - 06000 - Nice - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500021 - 95100 - Argenteuil - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500022 - 95300 - Pontoise - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500023 - 84000 - Avignon - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500024 - 44093 - Nantes - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500025 - 06000 - Nice - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500026 - 44600 - Saint Nazaire - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500027 - 94163 - Saint Mandé - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500028 - 34295 - Montpellier - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500029 - 13008 - Marseille - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500031 - 54500 - Vandoeuvre-lès-Nancy - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500032 - 59037 - Lille - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500035 - 97410 - Saint-Pierre - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500036 - 56100 - Lorient - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500037 - 49000 - Angers - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500038 - 85100 - Les Sables d'Olonne - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500039 - 97261 - Fort-de-France - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500040 - 72037 - Le Mans - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500041 - 80054 - Amiens - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500042 - 86000 - Poitiers - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500043 - 14033 - Caen - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500045 - 38700 - La Tronche - France | Contact (sur clinicalTrials) | ||||
| Investigational Site Number: 2500050 - 73000 - Chambery - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Male or female, 6 years or older.
- Initiating treatment with dupilumab for AD according to French-specific prescribing
information (≥ 12 years old: moderate to severe AD versus 6-11 years old: severe
AD). The decision of initiation of the treatment is independent to the study's
participation.
- Able to understand and complete study-related questionnaires.
- Signed informed consent form. For participants <18 years old, Informed consent form
signed by the parent/legal guardian and participant's assent obtained.
- Male or female, 6 years or older.
- Initiating treatment with dupilumab for AD according to French-specific prescribing
information (≥ 12 years old: moderate to severe AD versus 6-11 years old: severe
AD). The decision of initiation of the treatment is independent to the study's
participation.
- Able to understand and complete study-related questionnaires.
- Signed informed consent form. For participants <18 years old, Informed consent form
signed by the parent/legal guardian and participant's assent obtained.
- Patients who have a contraindication to the drug according to the French-specific
prescribing information label.
- Any condition that, in the opinion of the Investigator, may interfere with patient's
ability to participate in the study, such as short life expectancy, substance abuse,
severe cognitive impairment, or other comorbidities that can predictably prevent the
patient from adequately completing, as per routine care, the schedule of visits and
assessments.
- Patients currently participating in any interventional clinical trial.
- Patients previously treated with dupilumab.
- Patients under tutorship or curatorship; patients under safeguard of justice or
deprived of his/her liberty by an administrative or court decision.